Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma

Journal of Rheumatology

Volumn 33, Issue 2, 2006, Pages 269-274

  Chang, Betty ^a   Schachna, Lionel ^b   White, Barbara ^c   Wigley, Fredrick M ^c   Wise, Robert A ^c  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b AUSTIN HEALTH   (Australia)

^c JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

DLCO; Pulmonary hypertension; Risk factors; Scleroderma

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; ECHOCARDIOGRAPHY; FEMALE; HIGH RISK POPULATION; HUMAN; LONGITUDINAL STUDY; LUNG ARTERY PRESSURE; LUNG FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RISK FACTOR; SCLERODERMA; SYSTEMIC SCLEROSIS;

ADULT; COHORT STUDIES; COMORBIDITY; DISEASE PROGRESSION; ELECTROCARDIOGRAPHY; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; HYPERTENSION, PULMONARY; MALE; MARYLAND; MIDDLE AGED; RESPIRATORY FUNCTION TESTS; RISK FACTORS; SCLERODERMA, SYSTEMIC;

EID: 32144461709     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Battle RW, Davitt MA, Cooper SM, et al. Prevalence of pulmonary hypertension in limited and diffuse scleroderma. Chest 1996;110:1515-9.
2. Guinta A, Tirri E, Maione S, et al. Right ventricular diastolic abnormalities in systemic sclerosis: relation to left ventricular involvement and pulmonary hypertension. Ann Rheum Dis 2000;59:94-8.
3. Legerton CW, Smith EA, Silver RM. Systemic sclerosis (scleroderma): clinical management of its major complications. Rheum Dis Clin North Am 1995;21:203-16.
4. Kawat SM, Taichman DB, Archer-Chicko CL, Palevsky HI, Kimmel SE. Hemodynamics and survival in patients with pulmonary artery hypertension related to systemic sclerosis. Chest 2003;123:344-50.
5. Denton CP, Cailes JB, Phillips GD, Wells AU, Black CM, duBois RM. Comparison of doppler echocardiography and right heart catheterization to assess pulmonary hypertension in systemic sclerosis. Br J Rheumatol 1997;36:239-43.
6. Mukerjee D, St. George D, Knight C, et al. Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis. Rheumatology Oxford 2004;43:461-6.
7. Mukerjee D, St. Deorge D, Coleiro B, et al. Prevalence and outcome in systemic sclerosis associated pulmonary arterial hypertension: application of a registry approach. Ann Rheum Dis 2003;62:1008-93.
8. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
9. Erratum in: N Engl J Med 2002;346:1258.
10. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of Treprostimil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165:800-4.
11. Crapo RO. Reference spirometric values using techniques and equipment that meet ATS recommendations. Am Rev Respir Dis 1981;123:659-64.
12. Crapo RO, Morris AH. Standardized single breath normal values for carbon monoxide diffusing capacity. Am Rev Respir Dis 1981;123:185-9.
13. Crapo RO, Morris AH, Clayton PD, Nixon CR. Lung volumes in healthy nonsmoking adults. Clin Respir Physiol 1982;18:419-25.
14. Diggle PJ, Liang KY, Zeger SL. Analysis of longitudinal data. New York: Oxford University Press; 1994.
15. Schachna L, Chang B, White B, Wigley FM, Wise RA, Gelber AC. Older age at presentation and risk of pulmonary arterial hypertension in scleroderma. Chest 2003;124:2098-104.
16. Della Rossa A, Valentini G, Bombardiere S, et al. European multicentre study to define disease activity criteria for systemic sclerosis. I. Clinical and epidemiological features of 290 patients from 19 centres. Ann Rheum Dis 2001;60:585-91.
17. Steen VD, Graham G, Conte C, Owens G, Medsger TA. Isolated diffusing capacity reduction in systemic sclerosis. Arthritis Rheum 1992;35:765-70.
18. MacGregor AJ, Canavan R, Knight C, et al. Pulmonary hypertension in systemic sclerosis: risk factors for progression and consequences for survival. Rheumatology Oxford 2001;40:453-9.
19. Stupi AM, Steen VD, Owens GR, Barnes EL, Rodnan GP, Medsger TA Jr. Pulmonary hypertension in the CREST syndrome variant of systemic sclerosis. Arthritis Rheum 1986;29:515-24.
20. Simeon CP, Armadans L, Fonollosa V, et al. Survival prognostic factors and markers of morbidity in Spanish patients with systemic sclerosis. Ann Rheum Dis 1997;56:723-8.
21. Peters-Golden M, Wise RA, Schneider P, Hochberg M, Stevens MB, Wigley FM. Clinical and demographic predictors of loss of pulmonary function in systemic sclerosis. Medicine 1984;63:221-31.
22. Koh ET, Lee P, Gladman DD, Abu-Shakra M. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol 1996;35:989-93.
23. Poormoghim H, Lucas M, Fertig N, Medsger TA. Systemic sclerosis sine scleroderma: demographic, clinical, and serologic features and survival in forty-eight patients. Arthritis Rheum 2000;43:444-51.
24. Berger M, Haimowitz A, Van Tosh A, Berdoff RL, Goldberg E. Quantitative assessment of pulmonary hypertension in patients with tricuspid regurgitation using continuous wave Doppler ultrasound. J Am Coll Cardiol 1985;6:359-65.